NCT03456648View on ClinicalTrials.gov

Apixaban in End-stage Kidney Disease : A Pharmacokinetics Study

PHASE2CompletedINTERVENTIONAL

Enrollment

24

Participants

Timeline

Start Date

September 25, 2016

Primary Completion Date

August 24, 2018

Study Completion Date

August 24, 2018

Conditions

ESRDAnticoagulant Toxicity

Interventions

DRUG

apixaban

non-vitamin K oral anticoagulant (NOAC)

Trial Locations (1)

3000

University Hospitals Leuven, Leuven

Sponsors

Collaborators (1)

Bristol-Myers Squibb

All Listed Sponsors

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Universitaire Ziekenhuizen KU Leuven

OTHER